{
    "root": "b0558bc9-1b40-4588-b7cc-e46176c0ac4e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Ondansetron"
    },
    "value": "20250515",
    "ingredients": [
        {
            "name": "ONDANSETRON",
            "code": "4AF302ESOS"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1"
        },
        {
            "name": "SILICA",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "indications": "Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with:\n                  \n                     highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2\n                     \n                     initial and repeat courses of moderately emetogenic cancer chemotherapy\n                     radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen    \n                  \n                  Ondansetron orally disintegrating tablets also indicated for the prevention of postoperative nausea and/or vomiting.",
    "contraindications": "See full prescribing information for the recommended dosage in adults and pediatrics. (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg. ( 2.2 , 8.6 )",
    "warningsAndPrecautions": "Product:    50090-1128\n                  NDC:    50090-1128-0   4 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1128-1   30 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1128-2   10 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1128-3   10 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  2  in a  CARTON \n                  Product:    50090-1200\n                  NDC:    50090-1200-0   10 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1200-1   20 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1200-2   5 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  1  in a  CARTON \n                  NDC:    50090-1200-3   10 TABLET, ORALLY DISINTEGRATING in a BLISTER PACK   /  3  in a  CARTON",
    "adverseReactions": "Ondansetron orally disintegrating tablets are contraindicated in patients:\n                  \n                     known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation [see Adverse Reactions (6.2)]\n                     \n                     receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness"
}